Isotoosendanin inhibits triple-negative breast cancer metastasis by reducing mitochondrial fission and lamellipodia formation regulated by the Smad2/3-GOT2-MYH9 signaling axis.

Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE

Publication: 2009- : New York : Nature Publishing Group
Original Publication: Beijing, China : Science Press, c2000-

Triple Negative Breast Neoplasms*/pathology ; Triple Negative Breast Neoplasms*/metabolism ; Smad2 Protein*/metabolism ; Signal Transduction*/drug effects ; Mitochondrial Dynamics*/drug effects ; Pseudopodia*/drug effects ; Pseudopodia*/metabolism ; Myosin Heavy Chains*/metabolism ; Myosin Heavy Chains*/genetics ; Smad3 Protein*/metabolism; Humans ; Female ; Animals ; Mice ; Cell Line, Tumor ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Metastasis/prevention & control ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use

Triple-negative breast cancer (TNBC) is incurable and prone to widespread metastasis. Therefore, identification of key targets for TNBC progression is urgently needed. Our previous study revealed that isotoosendanin (ITSN) reduced TNBC metastasis by targeting TGFβR1. ITSN is currently used as an effective chemical probe to further discover the key molecules involved in TNBC metastasis downstream of TGFβR1. The results showed that GOT2 was the gene downstream of Smad2/3 and that ITSN decreased GOT2 expression by abrogating the activation of the TGF-β-Smad2/3 signaling pathway through directly binding to TGFβR1. GOT2 was highly expressed in TNBC, and its knockdown decreased TNBC metastasis. However, GOT2 overexpression reversed the inhibitory effect of ITSN on TNBC metastasis both in vitro and in vivo. GOT2 interacted with MYH9 and hindered its binding to the E3 ubiquitin ligase STUB1, thereby reducing MYH9 ubiquitination and degradation. Moreover, GOT2 also enhanced the translocation of MYH9 to mitochondria and thus induced DRP1 phosphorylation, thereby promoting mitochondrial fission and lamellipodia formation in TNBC cells. ITSN-mediated inhibition of mitochondrial fission and lamellipodia formation was associated with reduced GOT2 expression. In conclusion, ITSN prevented MYH9-regulated mitochondrial fission and lamellipodia formation in TNBC cells by enhancing MYH9 protein degradation through a reduction in GOT2 expression, thus contributing to its inhibition of TNBC metastasis.
Competing Interests: Competing interests: The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.)

Liver Int. 2018 Jul;38(7):1263-1272. (PMID: 29210177)
J Cancer. 2018 Oct 5;9(21):3839-3849. (PMID: 30410586)
Acta Pharm Sin B. 2023 Jul;13(7):2990-3007. (PMID: 37521871)
Cell Death Dis. 2019 Mar 11;10(3):239. (PMID: 30858360)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
Dev Biol. 2004 Jan 1;265(1):23-32. (PMID: 14697350)
Cell. 2011 Jun 24;145(7):1012-22. (PMID: 21703446)
Cell Metab. 2019 Aug 6;30(2):303-318.e6. (PMID: 31130467)
Cancer Discov. 2022 Oct 5;12(10):2237-2239. (PMID: 36196574)
Cell Death Dis. 2018 Jan 19;9(2):55. (PMID: 29352139)
Nat Rev Mol Cell Biol. 2014 Sep;15(9):577-90. (PMID: 25145849)
Cancer Commun (Lond). 2022 Jan;42(1):37-55. (PMID: 34981667)
Nat Cell Biol. 2018 Jul;20(7):755-765. (PMID: 29950571)
Nat Rev Mol Cell Biol. 2020 Apr;21(4):204-224. (PMID: 32071438)
Curr Opin Cell Biol. 2016 Apr;39:43-52. (PMID: 26896558)
Int J Oncol. 2020 Dec;57(6):1245-1261. (PMID: 33174058)
Signal Transduct Target Ther. 2021 Dec 1;6(1):401. (PMID: 34848680)
Clin Breast Cancer. 2009 Feb;9(1):29-33. (PMID: 19299237)
Nat Rev Mol Cell Biol. 2009 Jul;10(7):445-57. (PMID: 19546857)
Science. 2012 Aug 31;337(6098):1062-5. (PMID: 22936770)
FEBS Lett. 2021 Apr;595(8):1184-1204. (PMID: 33742459)
Cancer. 2001 Mar 1;91(5):964-71. (PMID: 11251948)
Research (Wash D C). 2023 Apr 11;6:0098. (PMID: 37223478)
Mol Ther. 2022 Jan 5;30(1):415-430. (PMID: 34450253)
Oncogene. 2013 Oct;32(40):4814-24. (PMID: 23128392)
Acta Pharmacol Sin. 2022 Oct;43(10):2666-2677. (PMID: 35228654)
Cell. 2016 Jul 28;166(3):555-566. (PMID: 27471965)
Cancer Res. 2022 Jul 5;82(13):2431-2443. (PMID: 35544764)
Acta Pharmacol Sin. 2023 Aug;44(8):1701-1711. (PMID: 36932232)
Br J Cancer. 2017 Aug 8;117(4):563-571. (PMID: 28664914)
Semin Cancer Biol. 2023 Jul;92:130-138. (PMID: 37068553)
Breast Cancer Res. 2020 Jun 9;22(1):61. (PMID: 32517735)
Cell Res. 2009 Feb;19(2):156-72. (PMID: 19153598)
Mol Cell. 2015 Feb 5;57(3):537-51. (PMID: 25658205)
Trends Biochem Sci. 2020 Jul;45(7):564-577. (PMID: 32291139)
Genetics. 1972 Feb;70(2):299-305. (PMID: 17248564)
Mol Oncol. 2019 Apr;13(4):959-977. (PMID: 30714292)
Front Cell Dev Biol. 2022 Mar 09;10:849962. (PMID: 35356277)
Mol Cell. 2015 Feb 5;57(3):521-36. (PMID: 25658204)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Lancet. 2017 Mar 18;389(10074):1134-1150. (PMID: 27865536)
Cell Death Differ. 2021 Dec;28(12):3251-3269. (PMID: 34131310)
Cancer Lett. 2020 Jan 28;469:89-101. (PMID: 31639424)
Front Endocrinol (Lausanne). 2018 Apr 27;9:211. (PMID: 29755415)
Cancer Res. 2022 Sep 16;82(18):3223-3235. (PMID: 35895805)

Keywords: DRP1; GOT2; MYH9; TNBC; isotoosendanin; mitochondrial fission

0 (Smad2 Protein)
0 (MYH9 protein, human)
0 (SMAD2 protein, human)
EC 3.6.4.1 (Myosin Heavy Chains)
0 (Smad3 Protein)
0 (SMAD3 protein, human)
0 (Antineoplastic Agents)

Date Created: 20240715 Date Completed: 20241121 Latest Revision: 20241123

20241123

PMC11579498

10.1038/s41401-024-01335-3

39009651